Multi-Nation Expert Panel Agrees On Biomarkers of Aging

For the first time, a multi-nation panel of aging experts reached a consensus to designate markers of aging, which could make aging intervention testing easier.

(An aged individual holding pills and supplements meant to work against aging | UCLA)

Aging &amp; Longevity

<p>Model: C57BL/6N mice<br />
Dosage: 1 g/kg carvedilol in food for one week followed by four weeks of PAGln treatment, consisting of 50 mg/kg per day by injection, and the same PAGln treatment for four weeks followed by 50 mg/kg per day of ABT263 via oral gavage for five days</p>


New Study Suggests Combining Senolytics with Blood Pressure Medication Counteracts an Aging Gut

Carvedilol, a blood pressure medication, and the senolytic agent ABT-263 both attenuate cellular senescence—an age-related, dysfunctional cellular state—driven by a gut bacterial metabolite in mice.

The Dementia Surge: New Study Projects Cases to Double by 2060

Researchers project dementia cases in the U.S. to double by 2060, revealing higher incidence in women, Black adults, and APOE ε4 carriers

Brain &amp; Neurons

Biotech Startup Aims to Harness New NAD+-Related Drug Against Aging

The longevity biotech company, MetaShape, has a new compound designed to restore cellular nicotinamide adenine dinucleotide (NAD+) and offset elevated cholesterol, cognitive decline, and neurodegeneration.

Will Interventions that Delay Aging in Animals Work for Humans?

Researchers have shown that using certain agents targeting hallmarks of aging (like inflammation) can extend lifespan in mice, yet human trials are just beginning to uncover whether they work in humans.

(Aged individuals may benefit from aging interventions that work in animal models | NAD.com)

Search Result: Aging Therapeutics

Expert Panel Agrees On Biomarkers of Aging for Testing Therapeutics

Combining Senolytics with Blood Pressure Medication Counteracts Gut Aging and Promotes Longevity, Suggests New Study

The Dementia Surge: New Study Projects Cases to Double by 2060

Biotech Startup Aims to Harness New NAD+-Related Drug Against Aging

Will Interventions that Delay Aging in Animals Work for Humans?